1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
A Little Poisoning Along the Road to ME/CFS
Looking at my symptoms, many of which are far less these days and some are gone, it would be easy to figure that I'd just been dealing with some heavy-duty menopausal issues.
Discuss the article on the Forums.

An XMRV Tool Box in the Federal Regustry August 27,2010

Discussion in 'XMRV Testing, Treatment and Transmission' started by illsince1977, Aug 28, 2010.

  1. illsince1977

    illsince1977 A shadow of my former self

    Messages:
    356
    Likes:
    22
    I couldn't find this posted previously. Hope it's not a duplicate. Remember Alan Dove picking the Federal Registry as his research pick of the week because it is now searchable? It sounds to me like the link to CFS is being taken seriously now. SAIC is a private defense contractor from what I understand.

    http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2010_register&docid=fr27au10-66.pdf

    VerDate Mar<15>2010 15:33 Aug 26, 2010 Jkt 220001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\27AUN1.SGM 27AUN1 WReier-Aviles on DSKGBLS3C1PROD with NOTICES
    Federal Register /Vol. 75, No. 166 / Friday, August 27, 2010 /Notices 52759

    An XMRV Tool Box: Expression
    Plasmids, Genes, and Proteins for All
    Components of the Xenotropic Murine
    Leukemia Virus-Related Virus (XMRV)
    Description of Invention: The
    xenotropic murine leukemia virusrelated
    virus (XMRV) has been
    implicated as a possible causative agent
    of prostate cancer and chronic fatigue
    syndrome (CFS). Scientists at the
    National Institutes of Health (NIH) and
    Science Applications International
    Corporation in Frederick, MD (SAIC–
    Frederick) have developed sixty four
    (64) protein expression plasmids for
    components of XMRV. One or more
    XMRV proteins made available through
    these expression plasmids could have
    clinical relevance to diagnosing or
    treating human disease. The work to
    develop this technology was performed
    in the Protein Expression Laboratory at
    SAIC–Frederick in collaboration with
    expert retrovirologists from the National
    Cancer Institute’s Frederick, MD
    campus, a site well-positioned to
    develop these expression plasmids from
    initial cloning to final validations. The
    development of these XMRV tools is
    expected to save researchers months in
    laboratory production time and
    thousands of dollars in labor costs.
    The XMRV strain utilized to generate
    these expression plasmids is a reference
    strain isolated from a human patient.
    Each expression plasmid encodes one of
    the ten proteins that comprise the
    XMRV retrovirus (matrix, p12, capsid,
    nucleocapsid, protease, reverse
    transcriptase, integrase, surface,
    transmembrane, and envelope). Nine of
    the ten XMRV proteins expressed by
    these clones have been successfully
    purified in large quantities using scaleup
    processes. The expression vectors
    were generated utilizing the Gateway
    cloning system and consist of Gateway
    entry clones, bacterial (Escherichia coli)
    expression clones, baculovirus
    expression clones, and mammalian
    expression clones. Expression of the
    appropriate XMRV protein from its
    corresponding expression clone has
    been confirmed. The entry clones have
    been validated for Gatewaysubcloning
    and the baculovirus clones have been
    validated for baculovirus production
    and can be transposed into baculoviral
    genomes. The plasmids have been fully
    mapped and sequenced and contain one
    or more elements to facilitate laboratory
    use, such as antibiotic resistance genes,
    specialized promoter sequences,
    maltose-binding protein and His tags,
    TEV protease sites, Kozak-ATG
    sequences, signal peptides, and other
    elements.
    Applications:
    Research tool whose large-scale
    production capability can be utilized to
    develop serological assays for detecting
    XMRV and other retroviruses to
    possibly establish these viruses as
    causative agents for CFS, prostate
    cancer, and other diseases with
    unknown origins.
    Collection of research tools that
    could be utilized to develop a complete
    set of diagnostic assays for detecting
    each of these XMRV proteins in patient
    samples.
    Research tool to serve as a platform
    for developing therapeutic moieties,
    such as neutralizing antibodies and
    other biologics, for treating prostate
    cancer, chronic fatigue syndrome, and
    any other disease where XMRV is later
    identified as the causative agent.
    A logical starting point for
    generating clinical-grade XMRV
    constructs for use in clinical vaccine,
    immunotherapy, and gene therapy
    studies.
    Advantages:
    First complete set of plasmids
    available for the expression of each
    XMRV protein individually: Researchers
    looking to study XMRV can save months
    of time and thousands of dollars by
    using this set of XMRV tools. The
    plasmids have been fully-mapped and
    validated for protein expression. This
    plasmid portfolio offers a variety of
    vectors for expressing these XMRV
    proteins including Gatewayentry
    clones, bacterial vectors, baculoviral
    vectors, and mammalian expression
    systems.
    Clones were developed from an
    XMRV isolate taken from a patient with
    a confirmed XMRV infection: The
    proteins produced by these expression
    plasmids are anticipated to have direct
    clinical applicability to human XMRV
    diseases.
    Launching pad for any commercial
    entity desiring to develop diagnostics or
    therapeutics for XMRV: This technology
    is likely to give companies in the
    prostate cancer arena or the emerging
    chronic fatigue syndrome market a
    competitive advantage for developing
    anti-XMRV products faster than
    competitors. The molecular targets
    needed as a starting point for
    therapeutic development are provided
    by this technology.
    Market: Apart from cancers of the
    skin, prostate cancer is the most
    common form of cancer found in men,
    especially in men over the age of 65. In
    the United States, an estimated 200,000
    men are diagnosed with prostate cancer
    each year and around 100 men die of
    the disease daily. About $5 billion
    dollars is spent annually on treatments
    for prostate cancer.
    The Center for Disease Control (CDC)
    estimates that over 1 million Americans
    are living with chronic fatigue
    syndrome and approximately 80% of
    these individuals are undiagnosed. This
    debilitating disease likely affects over 17
    million people worldwide and the cause
    of CFS is currently unknown. Those
    individuals diagnosed with CFS are a
    vocal patient group desiring expanded
    research into the cause of CFS and
    possible treatments and/or cures. In the
    United States alone, an estimated $9
    billion dollars is lost annually due to
    CFS-induced decreases in worker
    productivity.
    Inventors: Dominic Esposito (SAIC),
    Alan Rein (NCI), Stuart Le Grice (NCI),
    James Hartley (SAIC), William Gillette
    (SAIC), Ralph Hopkins III (SAIC), Troy
    Taylor (SAIC).
    Selected Publications:
    1. VC Lombardi, et al. Detection of an
    infectious retrovirus, XMRV, in blood
    cells of patients with chronic fatigue
    syndrome. Science 2009 Oct
    23;326(5952):585–589. [PubMed:
    19815723]
    2. A Urisman, et al. Identification of
    a novel Gammaretrovirus in prostate
    tumors of patients homozygous for
    R462Q RNASEL variant. PLoS Pathog.
    2006 Mar;2(3):e25. [PubMed: 16609730]
    Patent Status: HHS Reference No. E–
    155–2010/0—Research Tool. Patent
    protection is not being pursued for this
    technology.
    Licensing Status: Available for
    licensing under a Biological Materials
    License Agreement.
    Licensing Contact: Samuel E. Bish,
    Ph.D.; 301–435–5282; bishse@
    mail.nih.gov.
     
  2. pictureofhealth

    pictureofhealth XMRV - L'Agent du Jour

    Messages:
    534
    Likes:
    1
    Europe
    Hi illsince1977,

    I think there is a thread up and running for this.

    If you scan the forums I think it was started by BeesKnees and is entitled something like:
    "SAIC and NCI to Develop XMRV Toolkit".

    Good luck!
     
  3. illsince1977

    illsince1977 A shadow of my former self

    Messages:
    356
    Likes:
    22
    I'd be happy to delete this post if I could figure out how to do it.
     

See more popular forum discussions.

Share This Page